Rapid Growth of Circulating Tumor Cells (CTCs) Market Driven by Liquid Biopsy Advancements and Rising Cancer Incidence

The global Circulating Tumor Cells (CTCs) market expected to register a revenue CAGR of 11.5% during the forecast period

Reports And Data

NEW YORK , NY, UNITED STATES, June 1, 2023 /EINPresswire.com/ -- The global Circulating Tumor Cells (CTCs) market reached a value of USD 9.7 billion in 2022 and is projected to achieve a revenue CAGR of 11.5% during the forecast period. The growth of the market is primarily driven by advancements in the field of liquid biopsy and the increasing incidence of cancer.

Cancer prevalence is on the rise worldwide, with the World Health Organization (WHO) highlighting it as the second leading cause of death globally. This escalation in cancer cases necessitates the development of more efficient diagnostic and therapeutic options. Both patients and healthcare professionals recognize the value of identifying CTCs as an appealing choice due to its non-invasive nature, providing a means for cancer identification and monitoring without the need for invasive procedures.

Get Free Sample PDF (To Understand the Complete Structure of this Report [Summary + TOC]) @ https://www.reportsanddata.com/download-free-sample/5999

Segments Covered in the Report

The segmentation of the Circulating Tumor Cells (CTCs) market covers various aspects to provide a comprehensive understanding of the industry.

In terms of technology outlook, the market is divided into CTC Detection & Enrichment Methods and CTC Direct Detection Methods. CTC Detection & Enrichment Methods include immunocapture (label-based), positive selection, negative selection, size-based separation (label-free) such as membrane-based and microfluidic-based techniques, density-based separation

(label-free), and combined methods (label-free). On the other hand, CTC Direct Detection Methods encompass techniques like Surface-Enhanced Raman Spectroscopy (SERS), microscopy, and others. These technologies are utilized for the detection, enrichment, and analysis of CTCs.

The application outlook includes various purposes for CTC analysis. It encompasses clinical/liquid biopsy, which involves using CTCs for risk assessment, screening, monitoring, and research purposes. CTC analysis is also utilized in cancer stem cell and tumorogenesis research as well as drug/therapy development.

The product outlook comprises kits & reagents, blood collection tubes, and devices or systems. These products are essential for the collection, processing, and analysis of CTCs.

Regarding the specimen outlook, the market considers different sample types. Blood and bone marrow are the primary specimens used for CTC analysis, while other body fluids may also be employed in specific cases.

The regional scope of the market includes North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. These regions provide insights into the market dynamics, trends, and opportunities in different geographical areas.

By analyzing these segments, stakeholders can gain a comprehensive view of the CTC market, enabling them to make informed decisions and strategies based on the specific technologies, applications, products, specimens, and regions of interest.

Access Full Report Description with Research Methodology and Table of Contents @ https://www.reportsanddata.com/report-detail/circulating-tumor-cells-ctcs-market

Strategic development:

Menarini Silicon Biosystems made a significant strategic move on 19 June 2019 by introducing the DEPArray NxT system. This state-of-the-art instrument is designed for the isolation and analysis of rare cells, including Circulating Tumor Cells (CTCs). The DEPArray NxT system provides highly sensitive and precise analysis of CTCs, empowering researchers and clinicians to gain a deeper understanding of cancer biology and develop personalized treatment strategies that cater to individual patients' needs.

In another strategic development on 22 May 2020, F. Hoffmann-La Roche Ltd. completed the acquisition of Stratos Genomics, a U.S.-based company specializing in advanced DNA sequencing technologies. The acquisition, valued at approximately USD 17 million, aimed to expedite the progress of Roche's Next-Generation Sequencing (NGS) platform. This advanced platform has the potential to significantly enhance the detection and monitoring of CTCs in cancer patients, providing valuable insights for better diagnosis and treatment.

These strategic initiatives by Menarini Silicon Biosystems and F. Hoffmann-La Roche Ltd. demonstrate their commitment to advancing technologies and capabilities in the field of CTC analysis. By introducing cutting-edge systems and acquiring expertise in DNA sequencing, these companies aim to drive innovation and improve patient outcomes in the realm of cancer research and treatment.

Competitive Landscape:

The competitive landscape of the Circulating Tumor Cells (CTCs) market features several prominent players who play a crucial role in driving advancements and innovations in the field. These companies operate globally and offer a wide range of products and services for CTC detection, isolation, and analysis.

Thermo Fisher Scientific Inc. is a leading player in the market, offering a comprehensive portfolio of CTC-related products, including assays, instruments, and platforms for CTC detection and analysis.

Menarini Silicon Biosystems specializes in rare cell isolation and analysis, including CTCs. Their DEPArray NxT system provides advanced capabilities for the sensitive and accurate analysis of CTCs, aiding in cancer research and personalized treatment strategies.

QIAGEN N.V. is another major competitor, providing innovative solutions for CTC enrichment and analysis. Their product offerings include kits and assays for CTC isolation, as well as platforms for CTC characterization.

Hoffmann-La Roche Ltd. has a significant presence in the CTC market, leveraging their expertise in advanced DNA sequencing technologies. Their Next-Generation Sequencing (NGS) platform, enhanced through the acquisition of Stratos Genomics, aims to improve CTC detection and monitoring in cancer patients.
Other key players in the market include Advanced Cell Diagnostics, Inc., Fluxion Biosciences, Inc., Apocell, Inc., Biocept, Inc., Clearbridge Biomedics Pte Ltd, ANGLE plc, and IsoPlexis Corporation. These companies contribute to the competitive landscape by offering a variety of CTC-related products and services, ranging from assays and instruments to innovative technologies for CTC analysis.

Overall, the competitive landscape of the CTC market is characterized by the presence of established players who continually strive to enhance CTC detection and analysis capabilities. Through their contributions, these companies drive advancements in the field and contribute to the development of improved diagnostics and personalized treatment strategies for cancer patients.

In conclusion, the global Circulating Tumor Cells (CTCs) Market is highly competitive, with a few major players dominating the market. These companies are actively involved in developing new technologies and products, investing in research and development, and engaging in strategic partnerships and collaborations to maintain their market share and drive revenue growth.

Browse More Reports:

Nikhil Morankar
Reports and Data
+1 2127101370
email us here
Visit us on social media:
Facebook
Twitter
LinkedIn
